论文部分内容阅读
目的 观察HBsAg致敏树突状细胞治疗原发性肝癌合并HBV感染的疗效。方法 通过双盲法随机设立治疗组和对照组,治疗结束后,随访1年,观察两组治疗前后甲胎蛋白定量、HBV DNA定量、特异性细胞毒性T淋巴细胞(CTL)杀伤率和肝功能变化以及两组的复发转移率,生活质量及中位生存期情况。结果 与对照组比较甲胎蛋白定量、HBV DNA定量、特异性CTL杀伤率及复发和转移率差异均有显著性意义(P<0. 01);肝功能改善情况治疗组均明显优于对照组(P<0. 05);生活质量评分及中位生存期治疗组明显高于对照组(P<0. 01);同时甲胎蛋白滴度下降与HBV DNA滴度下降成正相关。结论 HBsAg致敏树突状细胞治疗原发性肝癌合并HBV感染,可达到治疗肝癌、预防肿瘤复发及转移、提高患者生活质量和延长患者生存期的目的。
Objective To observe the efficacy of HBsAg-sensitized dendritic cells in the treatment of primary liver cancer with HBV infection. METHODS: The treatment group and the control group were randomized by double-blind method. After the end of treatment, the patients were followed up for 1 year to observe the level of alpha-fetoprotein, HBV DNA, specific cytotoxic T lymphocyte (CTL) killing rate and liver function before and after treatment. Changes and recurrence rates, quality of life, and median survival of the two groups. Results Compared with the control group, the quantitative analysis of alpha-fetoprotein, HBV DNA, specific CTL killing rate, recurrence and metastasis rate were significant (P<0.01). The improvement of liver function was significantly better in the treatment group than in the control group. (P <0. 05); The quality of life score and median survival time in the treatment group were significantly higher than those in the control group (P <0. 01); at the same time, the decrease in alpha-fetoprotein titer was positively correlated with the decrease of HBV DNA titer. Conclusions HBsAg sensitized dendritic cells for the treatment of primary liver cancer with HBV infection can achieve the purpose of treating liver cancer, preventing tumor recurrence and metastasis, improving the quality of life of patients and prolonging the survival period of patients.